Evidence map›Paper›PMID 40546311›Full record

ArticleClinical case reports2025

Cholestatic Hepatic Injury Induced by Carbimazole: A Case Report and a Thorough Literature Review.

Bassem Al Hariri, Mohammed Omer Elbadawi Elhassan, Hadil Altaj Altrify Alsidig, Muad Abdi Hassan, Abdalrahman Mohammed Mostafa, Memon Noor Illahi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bassem Al HaririDepartment of Medicine Hamad Medical Corporation Doha Qatar.ORCID https://orcid.org/0000-0002-6858-3375
Mohammed Omer Elbadawi ElhassanMedical Education Department Hamad Medical Corporation Doha Qatar.ORCID https://orcid.org/0009-0005-7367-0974
Hadil Altaj Altrify AlsidigMedical Education Department Hamad Medical Corporation Doha Qatar.ORCID https://orcid.org/0009-0005-0951-2998
Muad Abdi HassanMedical Education Department Hamad Medical Corporation Doha Qatar.ORCID https://orcid.org/0009-0007-6128-1351
Abdalrahman Mohammed MostafaDepartment of Medicine Hamad Medical Corporation Doha Qatar.
Memon Noor IllahiDepartment of Medicine Hamad Medical Corporation Doha Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbimazole, a thionamide derivative, is widely used for hyperthyroidism but carries a rare risk of hepatotoxicity, including cholestatic injury. A 42-year-old man developed severe cholestatic jaundice 4 weeks after carbimazole initiation. Laboratory findings showed marked hyperbilirubinemia (peak: 650 μmol/L) with elevated ALP (366 U/L). Viral, autoimmune, and biliary causes were excluded. Liver biopsy confirmed cholestasis. Carbimazole was discontinued, corticosteroids initiated, and radioiodine therapy planned. Bilirubin levels gradually improved over 8 weeks. Carbimazole-induced cholestasis, though rare, necessitates prompt recognition and alternative hyperthyroidism management. Routine liver monitoring is crucial.

Indexed as

carbimazolecholestatic liver injurydrug‐induced liver injury (DILI)hepatotoxicityhyperthyroidismthionamide therapy

Identifiers

PMID40546311
PMCPMC12178830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.